ChEMBL logo

ChEMBL

spacer
ChEMBL Statistics
  Loading Statistics...
spacer

Compound Report Card

Compound Name and Classification

Compound ID CHEMBL255863
CHEMBL255863
Compound Name NILOTINIB
ChEMBL Synonyms NILOTINIB | TASIGNA | Nilotinib hydrochloride monohydrate | AMN 107
Max Phase 4 (Approved)
Trade Names TASIGNA
Molecular Formula C28H22F3N7O

Additional synonyms for CHEMBL255863 found using NCI Chemical Identifier Resolver

Compound Representations

Molfile Download MolFile
Canonical SMILES Cc1cn(cn1)c2cc(NC(=O)c3ccc(C)c(Nc4nccc(n4)c5cccnc5)c3)cc(c2) ...
Download SMILES
Standard InChI InChI=1S/C28H22F3N7O/c1-17-5-6-19(10-25(17)37-27-33-9-7-24(3 ...
Download InChI
Standard InChI Key HHZIURLSWUIHRB-UHFFFAOYSA-N

Sources

  • AstraZeneca Deposited Data
  • British National Formulary
  • Orange Book
  • PubChem BioAssays
  • Sanger Institute Genomics of Drug Sensitivity in Cancer
  • Scientific Literature
  • USP Dictionary of USAN and International Drug Names
  • WHO Anatomical Therapeutic Chemical Classification

Alternate Forms of Compound in ChEMBL


CHEMBL255863

Molecule Features

CHEMBL255863 compound icon
Drug Type:Synthetic Small Molecule Rule of Five:N First In Class:N Chirality:Achiral Molecule Prodrug:N Oral:Y Parenteral:N Topical:N Black Box:Y Availability Type:Prescription-only

Mechanism of Action

Mechanism of Action ChEMBL Target References
Tyrosine-protein kinase ABL inhibitor Tyrosine-protein kinase ABL DailyMed

Indications

MESH Heading MESH ID EFO ID EFO Term Max phase for indication References
Hypertension, PulmonaryD006976EFO:0001361pulmonary hypertension2ClinicalTrials
MelanomaD008545EFO:0000389cutaneous melanoma2ClinicalTrials
Colonic NeoplasmsD003110EFO:1001950colon carcinoma0ClinicalTrials
GliomaD005910EFO:0000326central nervous system cancer2ClinicalTrials
NeoplasmsD009369EFO:0000311cancer4ClinicalTrials
NeurilemmomaD009442EFO:0000693schwannoma2ClinicalTrials
Precursor Cell Lymphoblastic Leukemia-LymphomaD054198EFO:0000220acute lymphoblastic leukemia3ClinicalTrials
LeukemiaD007938EFO:0000565leukemia3ClinicalTrials
Gastrointestinal Stromal TumorsD046152Orphanet:44890Gastrointestinal stromal tumor3ClinicalTrials
Graft vs Host DiseaseD006086EFO:0004599acute graft vs. host disease2ClinicalTrials
Leukemia, Myelogenous, Chronic, BCR-ABL PositiveD015464EFO:0000339chronic myelogenous leukemia4ClinicalTrials
DailyMed
ClinicalTrials
Leukemia, Myeloid, AcuteD015470EFO:0000222acute myeloid leukemia2ClinicalTrials
Scleroderma, SystemicD012595EFO:0000717systemic scleroderma2ClinicalTrials
Alzheimer DiseaseD000544EFO:0000249Alzheimers disease2ClinicalTrials
ChordomaD002817Orphanet:178Chordoma1ClinicalTrials
NeoplasmsD009369EFO:0000616neoplasm4ATC
ClinicalTrials
Parkinson DiseaseD010300EFO:0002508Parkinson's disease2ClinicalTrials
ClinicalTrials
MelanomaD008545EFO:0000756melanoma2ClinicalTrials
MelanomaD008545EFO:0002617metastatic melanoma2ClinicalTrials
Synovitis, Pigmented VillonodularD013586EFO:1001106pigmented villonodular synovitis2ClinicalTrials

Clinical Data

ClinicalTrials.gov NILOTINIB
The Cochrane Collaboration NILOTINIB

Compound Bioactivity Summary

Compound Assay Summary

Compound Target Summary

Target Predictions

The two tables below display ChEMBL single-protein targets which are predicted to interact with CHEMBL255863. A 1uM and 10 uM cut-off have been applied to ChEMBL bioactivity data used to generate the respective models and the yellow coloured rows correspond to genuine predictions, i.e. targets not included in the original training set for this compound.


1uM


ChEMBL_ID Target Name Organism Score
CHEMBL5122 Discoidin domain-containing receptor 2 Homo sapiens 1.000
CHEMBL2007 Platelet-derived growth factor receptor alpha Homo sapiens 1.000
CHEMBL3905 Tyrosine-protein kinase Lyn Homo sapiens 1.000
CHEMBL1862 Tyrosine-protein kinase ABL Homo sapiens 1.000
CHEMBL5319 Epithelial discoidin domain-containing receptor 1 Homo sapiens 1.000
CHEMBL5145 Serine/threonine-protein kinase B-raf Homo sapiens 1.000
CHEMBL1936 Stem cell growth factor receptor Homo sapiens 1.000
CHEMBL4128 Tyrosine-protein kinase TIE-2 Homo sapiens 1.000
CHEMBL258 Tyrosine-protein kinase LCK Homo sapiens 1.000
CHEMBL4014 Tyrosine-protein kinase ABL2 Homo sapiens 1.000
CHEMBL3961 MAP kinase p38 beta Homo sapiens 0.999
CHEMBL4223 Tyrosine-protein kinase FRK Homo sapiens 0.999
CHEMBL1974 Tyrosine-protein kinase receptor FLT3 Homo sapiens 0.999
CHEMBL279 Vascular endothelial growth factor receptor 2 Homo sapiens 0.999
CHEMBL2599 Tyrosine-protein kinase SYK Homo sapiens 0.992
CHEMBL1913 Platelet-derived growth factor receptor beta Homo sapiens 0.984
CHEMBL260 MAP kinase p38 alpha Homo sapiens 0.979
CHEMBL2250 Tyrosine-protein kinase BLK Homo sapiens 0.974
CHEMBL2041 Tyrosine-protein kinase receptor RET Homo sapiens 0.920
CHEMBL301 Cyclin-dependent kinase 2 Homo sapiens 0.511



10uM


ChEMBL_ID Target Name Organism Score
CHEMBL5122 Discoidin domain-containing receptor 2 Homo sapiens 1.000
CHEMBL3905 Tyrosine-protein kinase Lyn Homo sapiens 1.000
CHEMBL2007 Platelet-derived growth factor receptor alpha Homo sapiens 1.000
CHEMBL1862 Tyrosine-protein kinase ABL Homo sapiens 1.000
CHEMBL5319 Epithelial discoidin domain-containing receptor 1 Homo sapiens 1.000
CHEMBL5145 Serine/threonine-protein kinase B-raf Homo sapiens 1.000
CHEMBL1936 Stem cell growth factor receptor Homo sapiens 1.000
CHEMBL4128 Tyrosine-protein kinase TIE-2 Homo sapiens 1.000
CHEMBL258 Tyrosine-protein kinase LCK Homo sapiens 1.000
CHEMBL4014 Tyrosine-protein kinase ABL2 Homo sapiens 1.000
CHEMBL279 Vascular endothelial growth factor receptor 2 Homo sapiens 1.000
CHEMBL1974 Tyrosine-protein kinase receptor FLT3 Homo sapiens 1.000
CHEMBL4223 Tyrosine-protein kinase FRK Homo sapiens 1.000
CHEMBL3290 Ephrin type-B receptor 2 Homo sapiens 1.000
CHEMBL2599 Tyrosine-protein kinase SYK Homo sapiens 0.998
CHEMBL2250 Tyrosine-protein kinase BLK Homo sapiens 0.997
CHEMBL3961 MAP kinase p38 beta Homo sapiens 0.995
CHEMBL260 MAP kinase p38 alpha Homo sapiens 0.993
CHEMBL4454 Tyrosine-protein kinase FGR Homo sapiens 0.988
CHEMBL2073 Tyrosine-protein kinase YES Homo sapiens 0.952

Calculated Compound Parent Properties

Mol. Weight Mol. Weight Monoisotopic ALogP #Rotatable Bonds Polar Surface Area Molecular Species
529.5 529.1838 6.36 6 97.62 NEUTRAL


HBA HBD #Ro5 Violations HBA (Lipinski) HBD (Lipinski) #Ro5 Violations (Lipinski)
7 2 2 8 2 2


ACD Acidic pKa ACD Basic pKa ACD LogP ACD LogD pH7.4 Aromatic Rings Heavy Atoms QED Weighted
12.94 5.63 4.42 4.41 5 39 0.27

Structural Alerts

There are no structural alerts for CHEMBL255863

Compound Cross References

ATC L - ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
L01 - ANTINEOPLASTIC AGENTS
L01X - OTHER ANTINEOPLASTIC AGENTS
L01XE - Protein kinase inhibitors
L01XE08 - nilotinib

ChemSpider ChemSpider:HHZIURLSWUIHRB-UHFFFAOYSA-N
DailyMed nilotinib hydrochloride monohydrate
PubChem SID: 124894351 SID: 124894352 SID: 99460838
Wikipedia Nilotinib

UniChem Cross References

View the UniChem Connectivity matches for CHEMBL255863



ACToR 641571-10-0
Atlas Nilotinib
BindingDB 50237710
Brenda 135566 24447
ChEBI 52172
ChemicalBook CB5966228
DrugBank DB04868
DrugCentral 1932
eMolecules 10645209
EPA CompTox Dashboard DTXSID5042663
FDA SRS F41401512X
Guide to Pharmacology 5697
Human Metabolome Database HMDB0015595
IBM Patent System C5E359F0259370D17A21633FC74FC9D0
LINCS LSM-1099
MolPort MolPort-003-987-089
Nikkaji J2.203.300J
PDBe NIL
PharmGKB PA165958345
PubChem 644241
PubChem: Thomson Pharma 16505655
Selleck Nilotinib
SureChEMBL SCHEMBL7901
ZINC ZINC000006716957

UniChem REST Service Call:
https://www.ebi.ac.uk/unichem/rest/verbose_inchikey/HHZIURLSWUIHRB-UHFFFAOYSA-N spacer
spacer